Splenic Micronodular T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: The Corticosteroid Pretreatment Hypothesis.
Apoptosis
Corticosteroids
Shrinkage
Splenic micronodular B-cell lymphoma
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
08
2021
accepted:
06
11
2021
pubmed:
10
11
2021
medline:
3
6
2022
entrez:
9
11
2021
Statut:
ppublish
Résumé
Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is derived from diffuse large B-cell lymphoma N.O.S., perhaps with some affinity with nodal THRLBCL. Of note, in contrast with the latter, the only lymph nodes involved in association with the splenic micronodular pattern of the disease are the splenic hilar lymph nodes. The possibility that corticosteroids, when prescribed prior to splenectomy, cause histopathological and functional modulations, apoptosis, necrosis, tissue shrinkage, which may obscure the diagnostic morphological features of this variant lymphoma and cause an underdiagnosis of this condition. The indications for glucocorticoid therapy are either related to the lymphoma itself, or else to other comorbidities, like asthma and autoimmune disorders. We propose that patients with the splenic subset of the disease are likely to have been prescribed corticosteroids prior to histopathologic examination of the involved spleen, causing disparate morphologies. However, a reviewer might accidentally dismiss the corticosteroid pretreatment which is thus overlooked. Apoptosis, induced by corticosteroids, is hypothesized as the major mechanism initiating the histopathological and functional changes in the splenic micronodular variant of the lymphoma.
Identifiants
pubmed: 34753138
pii: 000520791
doi: 10.1159/000520791
pmc: PMC9227669
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
310-317Informations de copyright
© 2021 The Author(s). Published by S. Karger AG, Basel.
Références
Am J Surg Pathol. 1994 Mar;18(3):323-4
pubmed: 8166840
Leuk Lymphoma. 2019 Dec;60(14):3426-3433
pubmed: 31287335
Immunopharmacology. 1998 Jul;40(1):67-76
pubmed: 9776480
J Immunol. 1999 Sep 15;163(6):3484-90
pubmed: 10477621
Clin Med Insights Blood Disord. 2020 Jun 10;13:1179545X20926188
pubmed: 32565679
Int J Surg Pathol. 2004 Jan;12(1):31-7
pubmed: 14765270
Cell Mol Life Sci. 2006 Jan;63(1):60-72
pubmed: 16314919
Virchows Arch. 2009 Oct;455(4):337-41
pubmed: 19763612
Haematologica. 2010 Mar;95(3):352-6
pubmed: 20207840
J Clin Oncol. 2002 Mar 1;20(5):1269-77
pubmed: 11870169
Leuk Lymphoma. 2011 Mar;52(3):425-8
pubmed: 21323522
Clin Lab Haematol. 2006 Dec;28(6):419-22
pubmed: 17105497
J Med Case Rep. 2021 Apr 14;15(1):163
pubmed: 33849639
Br J Cancer. 1995 May;71(5):937-41
pubmed: 7734316
Leuk Lymphoma. 2002 May;43(5):1129-32
pubmed: 12148896
Biochem Biophys Res Commun. 1997 Dec 18;241(2):519-24
pubmed: 9425303
Ann Diagn Pathol. 2008 Aug;12(4):290-292
pubmed: 18620998
Br J Haematol. 2009 Jul;146(2):126
pubmed: 19183196
Am J Surg Pathol. 2002 Nov;26(11):1458-66
pubmed: 12409722
Cancer. 1990 Mar 1;65(5):1072-3
pubmed: 2302658
Cancer. 2001 Jun 1;91(11):2001-9
pubmed: 11391578
Can J Neurol Sci. 2016 Sep;43(5):721-5
pubmed: 27468790
Am J Surg Pathol. 2003 Jul;27(7):903-11
pubmed: 12826882
Am J Surg Pathol. 2003 Jul;27(7):895-902
pubmed: 12826881